PT -期刊文章盟w·海丝特维瑟AU - Rolf莫莱森德Vriend盟Natasja M.W.H.雅斯贝尔斯盟——米歇尔·d·法拉利TI -舒马曲坦在临床实践中援助- 10.1212 / WNL.47.1.46 DP - 1996 7月01 TA -神经病学PG - 46 - 51 VI - 47 IP - 1 4099 - //www.ez-admanager.com/content/47/1/46.s首页hort 4100 - //www.ez-admanager.com/content/47/1/46.full Neurology1996 7月01;47 AB -长期和within-patient一致性的疗效和耐受性的皮下和口服舒马曲坦偏头痛研究通过2年的回顾性调查问卷邮寄我们的神经病学门诊诊所。首页受试者偏头痛患者或没有光环(N = 869)。我们测量长期使用舒马曲坦和within-patient一致性和随时间变化的头痛,头痛复发,后舒马曲坦和胸部症状。调查问卷是由735名(85%)患者返回;453 had used sumatriptan for nearly 28,000 attacks during 25 (median) months (92% >1 year). Sumatriptan provided headache relief, mostly within 2 hours, in 85% of patients in at least two-thirds of their attacks. Of all patients, 75% experienced (usually multiple) headache recurrences in at least some and 40% in (nearly) all attacks. Median time to recurrence was 8 to 12 hours (range 1 to 30). Recurrence of aura was reported as well. Over 2 years, efficacy of sumatriptan had waned in 18% of patients (mainly because of increase in headache recurrence) and improved in 12% (mainly because of reduction of headache recurrence or adverse events or increase of headache relief); the number of monthly doses of sumatriptan had increased in 20%, reduced in 35%, and not changed in 45% of patients. Chest symptoms occurred in up to 58% of patients in at least some and in up to 42% of patients in all attacks, causing discontinuation of sumatriptan in 10%. In total, 111 patients (25%) discontinued sumatriptan mainly because of headache recurrence, adverse events, insufficient headache relief, or high price. In most patients, the effects of sumatriptan were consistent within subjects and over time. In most patients, sumatriptan provided rapid headache relief. Multiple headache recurrence was the major limitation. Chest symptoms were frequent but usually not serious if patients were forewarned. NEUROLOGY 1996;47: 46-51